Oncoloxía médica
Servicio
University of California Los Angeles
Los Ángeles, Estados UnidosPublicacións en colaboración con investigadores/as de University of California Los Angeles (2)
2023
-
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
The Lancet, Vol. 401, Núm. 10379, pp. 821-832
-
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Targeted Oncology, Vol. 18, Núm. 5, pp. 639-641